Sociedad Americana de Hirudoterapia

Isolation, Characterization, and Evaluation of a Lytic Jumbo Phage Z90 Againstin American Eels ().

Research article published in Antibiotics (Basel, Switzerland) (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportResistencia antimicrobianaGenómica y proteómicaSeguridad y control de infeccionesZhang M et al. · Antibiotics (Basel, Switzerland), 2025

Abstract

Background:Aeromonas hydrophila is a common bacterial pathogen that causes hemorrhagic septicaemia in several farmed aquaculture species. Phage therapy is considered a promising and feasible alternative to antibiotic treatment. Methods: In this study, an A. hydrophila-infecting jumbo phage Z90 was isolated from an aquaculture pond. The biological characteristics, genomic features, and in vitro and in vivo experiments were investigated to evaluate its application potential. Results: Phage Z90 was a myovirus with distinctive curled tail fibers. Additionally, phylogenetic and genomic analyses found that the phage Z90 was a novel virus belonging to the genus Ferozepurvirus of the family Chimalliviridae. One-step growth curve analysis revealed that the phage Z90 was a lytic phage, exhibiting a short latency period of 20 min and a relatively large burst size of 270 ± 42 PFU/cell. The phage Z90 particles were stable at psychrotrophic and mesophilic temperatures (10-50 °C) and a wide range of pH (pH 3-12). Genomic analysis revealed that the phage Z90 did not contain any genes encoding toxins, virulence factors, or antibiotic resistance factors. In vivo analysis demonstrated that the phage Z90 protected American eels from A. hydrophila infection, greatly increasing eel survival rates and alleviating symptoms caused by bacterial infections. The comparison of different phage administration methods suggested that phage Z90 was better administered through intraperitoneal injection than immersion in aquaculture water. Moreover, the combination of phage Z90 and ampicillin improved the bactericidal effect and reduced the treatment dosage compared to antibiotics or phage alone. Conclusions: Altogether, the findings of this study indicate that the phage Z90 can serve as a promising biocontrol agent for the treatment of A. hydrophila infection in aquaculture.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Resumen

is a common bacterial pathogen that causes hemorrhagic septicaemia in several farmed aquaculture species. Phage therapy is considered a promising and feasible alternative to antibiotic treatment.

Por qué esto importa para la hirudoterapia

Este estudio aisló un fago bacteriano gigante lítico (Z90) activo contra *Aeromonas hydrophila*, un patógeno que causa septicemia hemorrágica en la acuicultura, y lo caracterizó como un mirovirus nuevo estable en un amplio rango de temperatura (10-50 C) y pH (3-12) y libre de genes de toxina, virulencia o resistencia a antibióticos; in vivo mejoró la supervivencia de anguilas americanas infectadas por *A. hydrophila*, funcionó mejor mediante inyección intraperitoneal y potenció el efecto bactericida cuando se combinó con ampicilina. La conexión con la hirudoterapia es tangencial y orientada al control de infecciones: *A. hydrophila* y especies de *Aeromonas* relacionadas son simbiontes intestinales de sanguijuelas medicinales y una fuente reconocida de infección de heridas post-terapia con sanguijuelas, por lo que el control basado en fagos de este patógeno es conceptualmente relevante para gestionar ese riesgo. Sin embargo, este es un estudio preclínico de terapia con fagos en peces sin sanguijuelas, sin humanos y sin datos de hirudoterapia, y no debe presentarse como evidencia sobre el manejo de infecciones en pacientes mediante terapia con sanguijuelas.

Citación

Isolation, Characterization, and Evaluation of a Lytic Jumbo Phage Z90 Againstin American Eels ().

Zhang M et al. · Antibiotics (Basel, Switzerland), 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.